摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-甲氧基硫代苯甲胺 | 2362-64-3

中文名称
4-甲氧基硫代苯甲胺
中文别名
4-甲氧基硫代苯甲酰胺
英文名称
p-methoxythiobenzamide
英文别名
4-methoxythiobenzamide;4-methoxybenzothioamide;4-methoxybenzenecarbothioamide
4-甲氧基硫代苯甲胺化学式
CAS
2362-64-3
化学式
C8H9NOS
mdl
MFCD00040993
分子量
167.232
InChiKey
WKWVTPKUHJOVTI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    145-149 °C(lit.)
  • 沸点:
    288.5±42.0 °C(Predicted)
  • 密度:
    1.194±0.06 g/cm3(Predicted)
  • 溶解度:
    DMF:30mg/mL; DMF:PBS (pH 7.2) (1:9):0.1 mg/mL; DMSO:25mg/mL;乙醇:1.4mg/mL
  • 稳定性/保质期:

    避免让氧化物接触。

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    67.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S36
  • 危险类别码:
    R20/22
  • WGK Germany:
    3
  • 海关编码:
    2930909090
  • 危险品运输编号:
    2811
  • 包装等级:
    II
  • 危险标志:
    GHS07
  • 危险性描述:
    H317
  • 危险性防范说明:
    P280

SDS

SDS:2c393c6ee3aae6c851a5b41847dd3d93
查看
Name: 4-Methoxythiobenzamide 98% Material Safety Data Sheet
Synonym:
CAS: 2362-64-3
Section 1 - Chemical Product MSDS Name:4-Methoxythiobenzamide 98% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
2362-64-3 4-Methoxythiobenzamide 98% unlisted
Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2362-64-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 148 - 152 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9NOS
Molecular Weight: 167.23

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Will not occur.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2362-64-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methoxythiobenzamide - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 2362-64-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2362-64-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2362-64-3 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-甲氧基硫代苯甲胺potassium carbonate 作用下, 以 为溶剂, 反应 8.0h, 生成 2-(4-methoxyphenyl)-4,5-dihydrooxazole
    参考文献:
    名称:
    A Mild and Efficient Synthesis of 2-Oxazolines via Transamidation–Cyclodehydrosulfurisation­ of Thioamides with 2-Aminoethanol
    摘要:
    Transamidation of thioamides with 2-aminoethanol, followed by cyclodehydrosulfurisation of the resultant N-(beta-hydroxyethyl)thioamides, has been utilised for the mild and efficient synthesis of 2-oxazolines. The developed protocol was found to be of general applicability.
    DOI:
    10.1055/s-0032-1317341
  • 作为产物:
    描述:
    5-p-methoxyphenyl-1,2,4-dithiazole-3-one 在 L-半胱氨酸 作用下, 以 aq. phosphate buffer 、 二甲基亚砜 为溶剂, 生成 4-甲氧基硫代苯甲胺
    参考文献:
    名称:
    [EN] COMPOUNDS FOR THIOL-TRIGGERED COS AND/OR H2S RELEASE AND METHODS OF MAKING AND USING THE SAME
    [FR] COMPOSÉS POUR LA LIBÉRATION DE COS ET/OU DE H2S DÉCLENCHÉE PAR THIOL ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
    摘要:
    本文揭示了一种化合物的实施例,该化合物能够在与含硫醇化合物反应时释放COS和/或H2S。该化合物实施例还可以在释放COS和/或H2S的同时产生可检测的信号(例如,荧光信号),和/或释放活性剂,如治疗剂。还公开了制备和使用该化合物实施例的方法。
    公开号:
    WO2019231503A1
  • 作为试剂:
    描述:
    1-(4-Fluorophenyl)-2-(4-methylsulfonylphenyl)-2-bromoethane-1-one4-甲氧基硫代苯甲胺二氯甲烷异丙醇 为溶剂, 以61%的产率得到5-[(4-methylsulfonyl)phenyl]-4-(4-fluorophenyl)-2-(4-methoxyphenyl)thiazole
    参考文献:
    名称:
    Substituted thiazoles for the treatment of inflammation
    摘要:
    描述了一类取代噻唑基化合物,用于治疗炎症性疾病。这些化合物由公式II定义,其中R.sup.1从氢化物、烷基、卤代烷基、氰基烷基、烷基胺基、芳基烷基、芳基胺基、杂环磺酰基烷基、杂环磺酰基卤代烷基、芳基胺基、芳氧基烷基、烷氧羰基、芳基(在可取代位置上可用一个或多个卤素和烷氧基选择的基团)和杂环(在可取代位置上可用一个或多个卤素和烷基选择的基团)中选择;其中R.sup.4从烷基和氨基中选择;其中R.sup.5从芳基和杂环中选择;其中R.sup.5在可取代位置上可用一个或多个卤素、烷基和烷氧基选择的基团进行取代;只要R.sup.5不是苯基在位置4时,当R.sup.1是α,α-双(三氟甲基)甲醇且R.sup.4是甲基;或其药用可接受盐。
    公开号:
    US05668161A1
点击查看最新优质反应信息

文献信息

  • Polymer-Supported Diaryl Selenoxide and Telluroxide as Mild and Selective Oxidizing Agents
    作者:Nan Xing Hu、Yoshio Aso、Tetsuo Otsubo、Fumio Ogura
    DOI:10.1246/bcsj.59.879
    日期:1986.3
    Polystyrene-bound diaryl selenoxide and telluroxide have been prepared, which behaved as mild oxidizing agents for thiols to disulfides, phosphines to phosphine oxides, hydroquinone and catechol to p- and o-benzoquinones, and thioketones to oxo compounds. The telluroxide completed these reactions in shorter periods or under milder conditions than the selenoxide. In addition, they effected novel solvent-dependent
    已经制备了聚苯乙烯结合的二芳基氧化物和氧化物,它们作为醇到二硫化物、膦到氧化膦、对苯二酚邻苯二酚到对和邻苯醌以及酮到氧代化合物的温和氧化剂。氧化物在比氧化物更短的时间内或在更温和的条件下完成这些反应。此外,他们还影响了代酰胺与 1,2,4-噻二唑或腈的新型溶剂依赖性反应,包括硫脲。在非酸性溶剂中,脱生成腈优先于氧化二聚生成 1,2,4-噻二唑,但酸性溶剂(如乙酸)促进了后者的反应。
  • Chemoselective Reactions of Tellurium Tetraethoxide towards Thioamides and Amides
    作者:Kazushi Omote、Yoshio Aso、Tetsuo Otsubo、Fumio Ogura
    DOI:10.1246/bcsj.67.1759
    日期:1994.6
    Tellurium tetraethoxide reacts with primary thioamides at room temperature, forming nitriles in high yields. On the other hand, the reactions with amides are largely temperature-dependent, giving predominantly esters at 80 °C and nitriles at a higher temperature. Similarly, tellurium tetraethoxide readily induces the C–N bond cleavage of ureas to give carbamates and amines.
    四乙氧基在室温下与伯酰胺反应,高效生成腈。另一方面,四乙氧基与酰胺的反应很大程度上依赖于温度,在80°C主要生成酯,而在更高温度下生成腈。同样,四乙氧基容易引发尿素中的C-N键断裂,生成氨基甲酸酯和胺。
  • [EN] FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS TRYCICLIQUES CONDENSÉS ET UTILISATIONS CORRESPONDANTES EN MÉDECINE
    申请人:SUNSHINE LAKE PHARMA CO LTD
    公开号:WO2018219356A1
    公开(公告)日:2018-12-06
    The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The invention also relates to the use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.
    本发明涉及一种融合三环化合物及其作为药物的用途,特别是作为治疗和/或预防乙型肝炎的药物。具体地,本发明涉及具有化学式(I)或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药的化合物,其中每个变量如规范中所定义。本发明还涉及将具有化学式(I)或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药用作药物,特别是作为治疗和/或预防乙型肝炎的药物。
  • [EN] METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE SYMPTÔMES NEUROLOGIQUES ASSOCIÉS À DES MALADIES LYSOSOMALES
    申请人:GENZYME CORP
    公开号:WO2021156769A1
    公开(公告)日:2021-08-12
    Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases. The methods include enhancing neuronal connectivity within the brain of a subject, increasing brain tissue volume, or preventing or delaying loss of brain tissue volume in a subject. Also provided are methods for monitoring the progression or regression of a neurological disorder, or assessing the onset of a neurological disorder, associated with a lysosomal storage disease, in which brain tissue volume of the subject is measured.
    提供了用于治疗或预防与溶酶体贮积病等相关的神经症状和疾病的方法。这些方法包括增强受试者大脑内的神经连接、增加大脑组织体积,或者预防或延迟受试者大脑组织体积的丧失。还提供了用于监测神经疾病的进展或退化,或评估与溶酶体贮积病相关的神经疾病的发作的方法,其中测量了受试者的大脑组织体积。
  • [EN] A THIONATION PROCESS AND A THIONATING AGENT<br/>[FR] PROCÉDÉ DE THIONATION ET AGENT DE THIONATION
    申请人:VIRONOVA AB
    公开号:WO2012104415A1
    公开(公告)日:2012-08-09
    A process for transforming a group >C=O (I) in a compound into a group >C=S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline P2S5·2 C5H5N as a thionating agent. A thionating agent which is crystalline P2S5·2 C5H5N
    将化合物中的一个羰基团(I)转化为一个代羰基团(II)或在给出代反应产物的反应中将其转化为羰基团(II)的互变异构形式的过程,通过使用晶体P2S5·2 C5H5N作为代试剂。一种晶体 ·2 作为代试剂
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯